Central IL community colleges among those receiving mental health grants
The Illinois Community College Board (ICCB) is providing $3,608,510 to community colleges statewide to support student mental health in 2025. These Mental Health Early Action on Campus (MHEAC) grants will help colleges expand mental health support programs and implement new strategies.
City of Springfield cracking down on code violations for massage parlors
Additionally, these funds will introduce new services, improve existing practices and target service gaps to assist in meeting the mental health needs of thousands of students on these campuses across Illinois.
'We know many college students nationwide face mental health challenges. A recent U.S. News survey revealed nearly 70% of college students report struggling with their mental health,' said ICCB executive director Brian Durham. 'This investment will help community colleges better meet the needs of students outside the classroom, contributing to their success in the classroom.'
The Central Illinois community colleges that applied for and are receiving MHEAC funding this fiscal year include:
Grant Recipient
Amount
Heartland Community College
$119,890
Lake Land College
$71,295
Lincoln Land Community College
$120,000
Parkland College
$119,710
Richland Community College
$120,000
Total Allocations
$550,895
Firefighters from across the Midwest come together in Vermilion Co. in first-of-its-kind forum
The 2023 Healthy Minds Study surveyed 800 campuses across the United States and found that 41% of students screened as positive for clinically significant symptoms of depression. Additionally, the survey found that 1 in 3 students screened as positive for anxiety.
Information from the Lumina Foundation State of higher Education 2024 Report indicates that 64% of students currently enrolled who recently considered dropping out of their programs said emotional stress/mental health concerns are significant reasons why.
Each college receiving grants will use them in at least one of four ways:
Develop and expand peer support programs
Expand the number of students served through local partnerships
Develop and expand mental health services targeting service gaps, emphasizing underserved students
Develop Medicaid and other reimbursement procedures for mental health services
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
an hour ago
- Fast Company
A Medicare experiment could change who gets Ozempic
If a new experiment pans out, Medicaid and Medicare could begin covering the costly weight loss drugs that price out many Americans who might want to try them. After killing a Biden-era plan with the same goal, the Trump administration is working on a five-year pilot program that would allow state Medicaid programs and Medicare's prescription plan to opt into covering drugs like Ozempic, Wegovy, Zepbound and Mounjaro for 'weight management,' The Washington Post reports. In its final months, the Biden administration proposed expanding Medicaid and Medicare coverage for popular weight loss drugs, extending it to roughly 7.5 million people enrolled in those programs. In April, the Trump administration tossed that plan – a move that was somewhat expected given Health and Human Services Secretary Robert F. Kennedy Jr.'s vocal opposition to the weight loss drugs that have taken America by storm. Now, something very similar appears to be back on the table. Differences of opinion Kennedy's view is at odds with other members of the Trump administration, including Dr. Mehmet Oz, the administrator of the Centers for Medicare & Medicaid Services (CMS). Oz, a former surgeon best known as a daytime television personality prior to joining the federal government, has long boosted weight loss drugs like Ozempic. 'I'll respect you no matter what your weight might be, but for those who want to lose a few pounds, Ozempic and other semaglutide medications can be a big help,' Oz said in a social media post in 2023. 'We need to make it as easy as possible for people to meet their health goals, period.' Oz has also been paid to promote the drugs in the past. In 2019, Ozempic maker Novo Nordisk sponsored a nine-minute long infomercial on Oz's daytime talk show praising the benefits of using Ozempic for Type 2 diabetes. On the other side of the coin, Kennedy at HHS is staunchly opposed to weight loss drugs like Ozempic and has made misleading claims about the class of drugs in the past. 'They're counting on selling it to Americans because we're so stupid and so addicted to drugs,' Kennedy said in an interview he shared on Instagram last year. Kennedy, a prominent figure in anti-vaccine circles before joining the Trump administration, has a long track record of elevating health conspiracy theories, even while promoting other common sense ideas around health and wellness. Kennedy, who opposes the use of many prescription medications, believes that the prominence of processed foods in the American diet is a root cause of many of the country's health woes. What is the status now? While Medicaid and Medicare don't evenly cover GLP-1 drugs like Ozempic for weight loss, 13 state Medicaid programs do offer coverage to treat obesity. For people on Medicaid and Medicare, coverage is much more widely available when GLP-1 drugs are prescribed to Type 2 diabetes. The Washington Post reports that the trial program is slated to start in April 2026 for Medicaid and in January 2027 for Medicare. The program is connected to the Center for Medicare and Medicaid Innovation, which experiments with new ways to lower costs and deliver coverage for people enrolled in those subsidized insurance programs. According to documents viewed by the Post, the program has yet to be finalized. Whether it goes into effect or not, the experimental plan to extend coverage shows that the anti-Ozempic faction of the Trump administration might find itself overruled when it comes to the weight loss drug.
Chicago Tribune
2 hours ago
- Chicago Tribune
UI Health ends gender-affirming pediatric surgery as Illinois joins federal lawsuit against Trump administration
Another Chicago hospital has ended gender-affirming pediatric surgery amid threats to its federal funding. But Illinois and 15 other states are fighting back in a federal lawsuit against the Trump administration for 'intimidating providers' into denying such care. On Friday, UI Health became the latest hospital to suspend gender-affirming surgical procedures for adolescents effective immediately, according to an announcement posted on the hospital's website. 'After careful review of recent federal government actions, UI Health has made the following changes to its gender-affirming surgical services,' the health system posted. 'Effective Aug. 1, 2025, UI Health has suspended gender-affirming surgical procedures for patients under age 19. Any patient working toward or scheduled for surgery will need to postpone surgery until they reach age 19.' UI Health is an academic health system associated with the University of Illinois Chicago. Its main facility is the 438-bed University of Illinois Hospital – the state's only public general hospital – which is located on Taylor Street at the center of the Illinois Medical District. In response to a request for comment Friday, UI Health forwarded its posted announcement and added a clarifying statement, leaving the door open to gender-affirming adolescent surgery in the future — if allowed by federal policy. 'We recognize the importance of gender-affirming care in supporting the health and well-being of our patients,' UI Health said in the statement. 'We are committed to working closely with affected individuals and families to ensure continuity of care and support. UI Health remains steadfast in its mission to provide compassionate, inclusive, and patient-centered care for all. We are closely monitoring federal updates to determine if or when to resume these services to patients under age 19.' The move by UI Health to suspend gender-affirming pediatric surgeries follows similar recent actions by other major Chicago hospitals. On July 18, UChicago Medicine announced it was discontinuing all gender-affirming pediatric care, while Rush University System for Health 'paused' hormonal care to new patients under the age of 18 beginning July 1. A January 28 executive action by President Donald Trump precipitated the gender-affirming care policy changes for hospitals across the U.S. Trump's order to prevent children under 19 from undergoing 'chemical and surgical mutilation' threatened to withhold federal research grants as well as Medicaid and Medicare reimbursement for institutions that provide such pediatric gender care services. The impact was immediate for some hospitals, with Lurie Children's Hospital pausing gender-affirming surgeries for patients younger than 19 in February, a policy which remains in place. Meanwhile, UI Health allegedly canceled an Illinois teenager's gender-affirming chest surgery, according to a February filing in a Maryland federal court. In the case, which is ongoing, the teen's mother said in a declaration the UI Health surgeon called her the day after Trump's executive order was issued to say the hospital 'was worried about losing millions of dollars in funding' and would not allow them to proceed with the scheduled surgery. On Friday, Illinois joined 15 other states in suing Trump, Attorney General Pam Bondi and the Justice Department for denying access to gender-affirming care for patients under 19. The Trump administration is 'intimidating providers into ceasing care through threats of civil and criminal prosecution,' according to the lawsuit filed in Massachusetts federal court. 'These threats have no basis in law,' the lawsuit states. 'No federal law prohibits, much less criminalizes, the provision or receipt of gender-affirming care for transgender adolescents. In fact, federal healthcare programs have reimbursed the provision of such care for years.' The lawsuit is seeking to declare Trump's order unconstitutional and unlawful, and to set aside subsequent federal actions targeting doctors, hospitals and pharmaceutical companies that provide 'medically necessary' gender-affirming care to adolescents. rchannick@
Gizmodo
2 hours ago
- Gizmodo
Feds Launch Experiment to Have Medicare Cover GLP-1 Weight Loss Drugs
The federal government may not have closed the window on paying for GLP-1 weight loss drugs like Ozempic and Zepbound after all. The Trump administration is reportedly planning to conduct an experiment that will allow some people to have obesity drugs covered by their Medicaid and Medicare plans. The Washington Post first broke the news Friday morning, having reportedly obtained documents from the Centers for Medicare and Medicaid Services outlining the plan. It would enable state Medicaid programs and Medicare Part D insurance plans to cover people's medications explicitly meant for 'weight management,' starting next year. Should the experiment go well, it could pave the way to widespread Medicare and Medicaid coverage of these expensive but effective drugs. A Staggering Number of U.S. Adults Are Eligible for Ozempic, Study Finds As things stand now, Medicare cannot directly cover any medications for treating obesity, including newer GLP-1 agents like semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound). Programs do have some leeway in providing coverage to people taking Ozempic and similar drugs for diabetes or certain obesity-related conditions, such as heart disease. Last year, the Biden administration proposed a rule designed to end this restriction, opening up coverage to some 7 million Americans on Medicare and Medicaid by 2026. In April this year, though, the Trump administration dropped the proposed rule entirely. However, Health Secretary Robert F. Kennedy Jr., who's previously criticized Ozempic in the past, did state at the time that the White House was still considering a 'framework' to expand coverage. Trump Is Promising to Lower Drug Prices. Don't Count on It According to the Washington Post, the Center for Medicare and Medicaid Innovation—an organization tasked with finding ways to lower health care costs and improve patient care—will be in charge of the experiment. Some specifics of the plan, including the exact criteria for eligibility, may still be up in the air, since the government could provide a window for public comment and further modification if it so chooses. As currently outlined, though, the experiment is expected to run for at least five years. Medicaid programs would reportedly be able to offer coverage starting in April 2026, while Medicare plans could do so in January 2027. The newest GLP-1 drugs like semaglutide have proven to be much more effective at helping people lose weight than diet and exercise alone. But their high costs and limited insurance coverage have impeded many people from obtaining or staying on these treatments long-term (some users are also unable to tolerate the common gastrointestinal side effects they cause). That said, this proposed plan is the latest sign that these cost issues are improving. The list prices of Ozempic and similar drugs have started to drop as of late; for instance, America's upstairs neighbor Canada is expected to approve the first generics of Ozempic early next year (that probably won't happen until 2030 in the U.S., though). The likely arrival of new approved competitors to these drugs as early as next year is also expected to drive down prices in general.
